Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Authors
Keywords
Calorie restriction mimetics, Calorie restriction facilitators, Consensus, GLP-1 RA, Incretin-based therapies, Type 2 diabetes mellitus
Journal
Diabetes Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-30
DOI
10.1007/s13300-019-0669-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
- (2018) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
- (2018) Lorraine Lipscombe et al. Canadian Journal of Diabetes
- Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes
- (2018) Louis S. Matza et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
- (2018) Serge A. Jabbour et al. DIABETES OBESITY & METABOLISM
- Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States
- (2018) Anita M. Loughlin et al. DIABETES OBESITY & METABOLISM
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis
- (2018) Panagiotis Andreadis et al. DIABETES OBESITY & METABOLISM
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
- (2018) Mark Warren et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
- (2018) Alan J. Garber et al. Endocrine Practice
- Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus PatientsNovelty and Significance
- (2018) Lennart Tonneijck et al. HYPERTENSION
- RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
- (2018) Sarita Bajaj International Journal of Diabetes in Developing Countries
- The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
- (2018) Takahiro Yajima et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- EFFECT OF LIRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN ELDERLY PATIENTS IN THE LEADER TRIAL
- (2018) Matthew Gilbert et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations
- (2018) Ian Blumer et al. POSTGRADUATE MEDICINE
- Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
- (2018) Rodrigo Oliveira Moreira et al. Diabetology & Metabolic Syndrome
- Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
- (2018) Francesco Giorgino et al. Patient Preference and Adherence
- GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
- (2018) María Isabel del Olmo-Garcia et al. Journal of Diabetes Research
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2018) Fang-Hong Shi et al. Frontiers in Pharmacology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
- (2018) James G. Boyle et al. CLINICAL SCIENCE
- GLP-1 receptor agonists and cardiovascular outcome trials: An update
- (2018) Eirini Andrikou et al. Hellenic Journal of Cardiology
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
- (2017) Alexander Niessner et al. EUROPEAN HEART JOURNAL
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials
- (2017) Michael E. Trautmann et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option
- (2017) Gauri Dhir et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE
- (2017) Susan Cornell JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome
- (2017) Mohit Bhandari et al. OBESITY SURGERY
- The effects of GLP-1 analogues on pre-diabetes of the children
- (2017) Qing-Xia Zhou et al. Experimental and Therapeutic Medicine
- GLP-1 receptor agonists in the treatment of polycystic ovary syndrome
- (2017) Elizabeth Mary Lamos et al. Expert Review of Clinical Pharmacology
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
- (2017) Michael Feher et al. Diabetes Therapy
- Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
- (2017) Michael Feher et al. Diabetes Therapy
- Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety
- (2017) Elizabeth P. Mills et al. Therapeutic Advances in Endocrinology and Metabolism
- Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
- (2016) Keith C. Ferdinand et al. Cardiovascular Diabetology
- Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis
- (2016) Carrie McAdam-Marx et al. CLINICAL THERAPEUTICS
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and
- (2016) M. A. Boustani et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial
- (2016) S. T. Azar et al. DIABETES OBESITY & METABOLISM
- Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment
- (2016) G. E. Umpierrez et al. DIABETES OBESITY & METABOLISM
- Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
- (2016) M. Odawara et al. DIABETES OBESITY & METABOLISM
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
- (2016) Katherine R. Tuttle et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial
- (2016) T. S. Bailey et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis
- (2016) Wayne H.-H. Sheu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome
- (2016) Francesco Orio et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes
- (2016) Ildiko Lingvay et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
- (2016) Amalia Gastaldelli et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery
- (2016) Juan J. Gorgojo-Martínez et al. Surgery for Obesity and Related Diseases
- A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
- (2016) Sheena Kayaniyil et al. Diabetes Therapy
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
- (2016) Amrita Ostawal et al. Diabetes Therapy
- A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
- (2016) Sheena Kayaniyil et al. Diabetes Therapy
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
- (2016) Amrita Ostawal et al. Diabetes Therapy
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
- (2016) Lin Zhang et al. Scientific Reports
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
- (2015) B. Cariou DIABETES & METABOLISM
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials
- (2015) M. Reaney et al. DIABETES OBESITY & METABOLISM
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
- (2015) A. Ahmann et al. DIABETES OBESITY & METABOLISM
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Diabetes Technology & Therapeutics
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2015) Laura J Carbone et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
- (2015) Donna Ryan et al. Obesity
- Clinical Effectiveness of Exenatide in Diabetic Patients Waiting for Bariatric Surgery
- (2015) P. Iglesias et al. OBESITY SURGERY
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- Diabetes Care in India
- (2015) Shashank R. Joshi Annals of Global Health
- Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
- (2015) Sarah L. Anderson et al. Therapeutic Advances in Chronic Disease
- Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
- (2014) Francisco Kerr Saraiva et al. Cardiovascular Diabetology
- Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials
- (2014) Troels M. Jensen et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
- (2014) L. J. Schmidt et al. DIABETES OBESITY & METABOLISM
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
- (2014) Z. Skrivanek et al. DIABETES OBESITY & METABOLISM
- Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
- (2014) Y. G. Kim et al. DIABETES OBESITY & METABOLISM
- Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) David J. Klein et al. Diabetes Technology & Therapeutics
- Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme
- (2014) Denis Raccah et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
- (2014) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
- (2014) Xing-Chun Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- (2014) L. Li et al. BMJ-British Medical Journal
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
- (2014) Sanjay Kalra Diabetes Therapy
- Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis
- (2014) Liza Haqq et al. Endocrine Connections
- Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective
- (2014) Mala Dharmalingam Therapeutic Advances in Endocrinology and Metabolism
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
- (2013) C. Kapitza et al. DIABETES OBESITY & METABOLISM
- Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors
- (2013) Yuhua Shi et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials
- (2013) Michael Grimm et al. POSTGRADUATE MEDICINE
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- (2013) Martin Lorenz et al. REGULATORY PEPTIDES
- Obesity and Dyslipidemia in South Asians
- (2013) Anoop Misra et al. Nutrients
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
- (2013) Elena Ceccarelli et al. Frontiers in Endocrinology
- The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis
- (2012) Nitika A. Gupta et al. AMERICAN JOURNAL OF PATHOLOGY
- GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
- (2012) Dhanwantee Mundil et al. Diabetes & Vascular Disease Research
- Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
- (2012) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
- (2012) R. Pencek et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- Exenatide Twice Daily: Analysis of Effectiveness and Safety Data Stratified by Age, Sex, Race, Duration of Diabetes, and Body Mass Index
- (2012) Richard Pencek et al. POSTGRADUATE MEDICINE
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- GLP-1 receptor agonists and HBA1ctarget of
- (2011) K. Esposito et al. CURRENT MEDICAL RESEARCH AND OPINION
- The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review
- (2011) J. H. Best et al. DIABETES OBESITY & METABOLISM
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Psychological and quality of life changes in patients using GLP-1 analogues
- (2011) Paul Grant et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci
- (2011) Jaspal S Kooner et al. NATURE GENETICS
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
- (2011) Shvetank Sharma et al. PLoS One
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
- (2010) B. W. Bode et al. DIABETES OBESITY & METABOLISM
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Glycaemic control with liraglutide: the phase 3 trial programme
- (2010) P. Raskin et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
- The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
- (2009) L. Blonde et al. DIABETES OBESITY & METABOLISM
- The effects of glucagon-like peptide-1 on the beta cell
- (2009) T. Vilsbøll DIABETES OBESITY & METABOLISM
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Diabetes in Asia
- (2009) Ambady Ramachandran et al. LANCET
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- The Effect of a Hypocaloric Diet with and without Exercise Training on Body Composition, Cardiometabolic Risk Profile, and Reproductive Function in Overweight and Obese Women with Polycystic Ovary Syndrome
- (2008) Rebecca L. Thomson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- The incretin system and its role in type 2 diabetes mellitus
- (2008) J HOLST et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started